Is neomycin (antibiotic) polymyxin (antibiotic) ototoxic?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Neomycin Polymyxin Is Ototoxic

Yes, neomycin polymyxin is definitively ototoxic and can cause irreversible damage to the vestibulocochlear nerve, resulting in permanent hearing loss and vestibular dysfunction. 1

Mechanism and Risk of Ototoxicity

Neomycin, an aminoglycoside antibiotic, is known to cause ototoxicity through:

  • Damage to sensory cells and neurons in the inner ear through free radical generation 2
  • Irreversible vestibulocochlear nerve damage 1
  • Primarily cochleotoxic effects (affecting hearing more than balance) 2

The ototoxicity typically manifests as:

  • Hearing loss (often detected first)
  • Tinnitus
  • Vertigo
  • Loss of balance 1

Risk Factors for Ototoxicity

Several factors increase the risk of neomycin-induced ototoxicity:

  • Renal impairment - significantly increases risk 3, 4
  • Prolonged use - higher risk with extended treatment 1
  • Advanced age - elderly patients are more susceptible 1, 3
  • Concurrent use of other ototoxic medications such as:
    • Loop diuretics (ethacrynic acid, furosemide)
    • Other aminoglycosides
    • Vancomycin
    • Cisplatin 3

Routes of Administration and Risk

Ototoxicity can occur with multiple routes of administration:

  • Oral administration - systemic absorption occurs even with oral neomycin 3, 5
  • Topical application - can cause severe, permanent hearing deficit, especially with:
    • Prolonged application
    • Application to large surface areas
    • Application to damaged skin or mucous membranes 4
  • Ear drops - can cause severe inner ear damage when applied to the middle ear through a perforated tympanic membrane 6

Monitoring Recommendations

For patients receiving neomycin (especially high-risk patients):

  • Baseline audiometry before starting treatment 1
  • Monthly audiometric testing during treatment 1
  • Final audiometry 2 months after the final dose 1
  • Monitor for early symptoms of ototoxicity:
    • Changes in hearing
    • Tinnitus
    • Vertigo
    • Balance problems 1

Important Clinical Considerations

  • Ototoxicity is often delayed in onset - symptoms may not appear until after treatment has ended 3
  • Hearing loss is typically irreversible once it occurs 1, 3
  • Ototoxicity on audiogram is defined as a 20 dB loss from baseline at any one test frequency or a 10 dB loss at any two adjacent test frequencies 1
  • If ototoxicity is detected, neomycin should be discontinued immediately, but the hearing loss that has occurred is likely permanent 1

Prevention Strategies

  • Avoid use in patients with known renal impairment 3
  • Avoid concurrent use with other ototoxic medications 1, 3
  • Use for the shortest duration possible 3
  • Consider alternative antibiotics in high-risk patients 3
  • Monitor renal function regularly during treatment 1
  • Instruct patients to report any auditory or vestibular symptoms immediately 1

Neomycin polymyxin should be used with extreme caution, especially in high-risk populations, and only when the benefits clearly outweigh the significant risk of permanent hearing loss.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Aminoglycoside-induced ototoxicity.

Current pharmaceutical design, 2007

Research

Hearing loss following the application of topical neomycin.

The Journal of burn care & rehabilitation, 1988

Research

Ototoxicity of oral neomycin and vancomycin.

The Laryngoscope, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.